权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction

了解 T 细胞内在雄激素受体活性如何影响细胞分化和功能障碍

基本信息

批准号：
10445347
负责人：
Amy E Moran
金额：
$ 54.46万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-06 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10445347
关键词：
2019-nCoV Activities of Daily Living Androgen Antagonists Androgen Receptor Androgen Response Element Androgens Autoimmune Diseases Binding Biological Assay Biopsy CD8-Positive T-Lymphocytes CD8B1 gene Cancer Etiology Cancer Model Cancer Patient Castration Cell Differentiation process Cell Nucleus Cell physiology Cells Cessation of life Chromatin Chromatin Remodeling Factor Chronic Clinical Trials Complex DNA Binding DNA receptor Disease EZH2 gene Effectiveness Epigenetic Process Experimental Models Functional disorder Gene Expression Genes Genetic Genetic Transcription Genomics Goals Gonadal Steroid Hormones Grant Health Sciences Hormones Human Immunity Immunosuppression Immunotherapy In complete remission Interferons Leukocytes Malignant Neoplasms Malignant neoplasm of prostate Mediating Metastatic Prostate Cancer Oregon Outcome PD-1 blockade PD-L1 blockade Patients Pharmacology Precipitation Predisposition Prostate Sarcoma Receptor Inhibition Receptor Signaling Regulator Genes Repression Resistance Risk Role Sampling Shapes T cell differentiation T cell response T-Lymphocyte Testing Testosterone Time Transcriptional Regulation Tumor Antigens Tumor Immunity United States Universities Viral Virus Woman XCL1 gene androgen deprivation therapy androgen sensitive antagonist anti-PD-L1 therapy anti-PD1 therapy antigen-specific T cells cancer immunotherapy castration resistant prostate cancer effector T cell enzalutamide exhaust exhaustion experimental study histone methyltransferase immune checkpoint blockade improved in silico inhibitor male men mortality mouse model novel novel therapeutic intervention pathogen programmed cell death ligand 1 programmed cell death protein 1 prostate cancer model receptor binding recruit response sex single-cell RNA sequencing small molecule inhibitor standard of care treatment strategy tumor tumor microenvironment

项目摘要

PROJECT SUMMARY Androgens are well known to be immunosuppressive, yet cancer immunotherapy is used without consideration of local androgen concentrations or the sex of the patient. We present evidence that targeting the androgen receptor is necessary for effective T cell-specific immunotherapy in mouse models of prostate cancer and sarcoma and in a human clinical trial of metastatic prostate cancer. In patient biopsies, we observed a striking correlation between low androgen receptor activity in CD8 T cells and response to PD-1 targeted immunotherapy. We validated our observations in a novel mouse model of castration resistant prostate cancer and demonstrated a requirement for androgen receptor inhibition to permit effective PD-L1 immunotherapy. Moreover, tumor regression required CD8 T cells suggesting T cell intrinsic AR activity could regulate response to immunotherapy. Extending these studies, we isolated activated CD8 T cells and observed a strong association of androgen receptor with chromatin modifiers. Performing in silico experiments revealed canonical androgen response elements in open chromatin regions of the Ifng and Gzmb loci. We observed binding of the androgen receptor within these regions and importantly, the ability to inhibit this interaction with a small molecule inhibitor. Inhibiting this interaction increased the functional capacity of dysfunctional CD8 T cells; a functional state further amplified by PD-L1 blockade. Taken together, these observations suggest that androgen receptor signaling could enforce the dysfunctional chromatin state of T cells limiting reinvigoration by checkpoint blockade. To the best of our knowledge this is the first experimental model to establish a direct role for androgen receptor activity on regulating responsiveness to immunotherapy. The goal of this proposal is to understand the mechanism(s) by which androgen receptor activity in CD8 T cells limits the effectiveness of cancer immunotherapy. We hypothesize that androgen receptor activity in CD8 T cells limits functional re-invigoration to immune checkpoint blockade by transcriptional and epigenetic repression of effector genes. We will test this hypothesis in the following Aims. 1) Evaluate whether AR activity represses T cell effector genes by direct DNA binding; 2) Determine whether AR signaling enforces a repressive chromatin state in dysfunctional CD8 T cells; and 3) Determine whether loss of T cell intrinsic AR is sufficient to restore responsiveness to checkpoint blockade. Together, these studies provide a framework for understanding hormone mediated resistance to cancer immunotherapy. Importantly, we will gain a critical understanding of how androgen could limit effective immunotherapy in prostate cancer patients and anticipate that our observations will be applicable beyond this disease to improve immunotherapy outcomes in cancers where androgens are present.

项目总结